This page is no longer being updated. For the latest updates on COVID-19, including vaccines and treatments, please visit www.cdc.gov/coronavirus. Healthcare professionals, please visit aspr.hhs.gov/COVID-19/Pages/default.aspx and www.covid19treatmentguidelines.nih.gov.
ACTIV-4 HOST TISSUE (HT): NOVEL EXPERIMENTAL COVID THERAPIES AFFECTING HOST RESPONSE (NECTAR)
NECTAR is a nationwide clinical trial studying new treatments to see if they help patients in the hospital with COVID‑19 recover.
Image
WHAT IS THIS STUDY ABOUT?
The NECTAR trial is a nationwide clinical research study looking at several new medications to treat COVID-19. The focus of this study is to find new ways to treat the overactive immune response caused by COVID-19 infection. Treating and preventing these complications may help prevent lung damage and worsening of COVID-19 for patients in the hospital. The NECTAR trial is trying to answer questions like:
- Will these medications help patients get better by preventing or treating lung damage caused by COVID-19?
- Can we help people in the hospital with COVID-19 get off oxygen and go home faster?
If you participate in the NECTAR trial, you will still receive standard medical treatment to treat COVID-19 symptoms. In addition, you may receive the study medication or a placebo that looks like the medication but does not have any active drugs in it. You will be randomly assigned to a treatment group, which means that neither you nor your research team will know which group you are assigned to. Joining this study is voluntary and you can choose to stop at any time.
Participation in the NECTAR clinical trial is for 90 days, but you do not need to be in the hospital this entire time. You will receive the study treatment for up to 14 days, depending on which medication you receive. In the hospital, you will be monitored daily for side effects and some blood will be drawn. After leaving the hospital, you will be contacted by phone about how you are feeling. You will be asked if you are still using oxygen and how you are recovering, at 60 days and 90 days after joining the study.
WHO CAN JOIN THIS STUDY?
If you recently tested positive for COVID-19, this study may be for you. Clinical trials testing COVID-19 treatments need people from diverse backgrounds. This will help researchers find treatments that are safe and work for more people. Each person who takes part in the ACTIV-4HT NECTAR study will meet specific conditions, including:
Image
Age
At least 18 years old
Image
COVID-19 Status
Currently in the hospital due to COVID-19
Image
Symptoms
Serious COVID-19 symptoms
HOW CAN I JOIN THIS STUDY?
If you are interested in joining the ACTIV-4HT NECTAR clinical trial or you would like more information:
Image
RESOURCES
Image
NECTAR STUDY FACT SHEET
ANSWERS TO OTHER QUESTIONS YOU MIGHT HAVE
Image
A clinical research study helps experts find treatments that are safe and effective. It is important that these studies include people from diverse backgrounds. This helps researchers develop new treatments that will work for more people.
The placebo looks like the study medication but does not have any active ingredients in it. Researchers compare how people react to both placebos and medications to learn if the medication is safe and helps people recovery more quickly. If you join this study, you will get the usual care for COVID-19.
Yes. Taking part in this clinical trial is voluntary; it is your choice. You can change your mind at any time and leave the study.